HOXA9 and CD163 potentiate pancreatic ductal adenocarcinoma progression
In conclusion, HOXA9 could potentiate PDAC progression by stimulating CD163 expressed TAM attraction in tumors. HOXA9 and CD163 could participate in PDAC therapy. HOXA9 and CD163 could be predictors of worse prognosis and shorter survival in PDAC.
Authors
- Aiat Shaban Hemida (ORCID: https://orcid.org/0000-0002-3781-8872)
- Mohamed M. Radwan (ORCID: https://orcid.org/0000-0002-8074-2535)
- Mona Saeed Tantawy
Institutions
- Menoufia University (EG)
Publication Details
- Journal
- Diagnostic Pathology
- Published
- 2024-10-26
- DOI
- https://doi.org/10.1186/s13000-024-01563-5
- Citations
- 4
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 1.14